Phase 3 Readout
GSK: Phase 3 Topline: A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S
June 18, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 18, 2026
- Company
- GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout
Phase 3 Topline: A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S
- Indication
- Cough; Refractory Chronic Cough